IP Library › Granted Patent US 9,005,609
Granted Patent B2
US 9,005,609 · App. 12/750,334 · Granted Apr 14, 2015

Hemostatic compositions containing sterile thrombin

Inventors: Sanyog M. Pendharkar (Pune, IN); Anne J. Gorman (Hightstown, NJ)
Assignee: Ethicon, Inc.
A61K9/0019A61K9/10A61K9/19A61K38/36A61K38/363A61K38/39A61K38/4833A61K47/36A61K47/42A61L24/104A61L24/108A61L26/0028A61L26/0042A61L26/0095A61L2400/04C12N9/6429C12Y304/21005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,005,609
App. No.
12/750,334
Granted
Apr 14, 2015
Kind
B2
Abstract

The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and that is substantially insoluble in the liquid phase, and sterile thrombin, each of which is substantially homogenously dispersed throughout the continuous liquid phase, and methods for making such compositions.

Claims (9)

1. A sterile hemostatic composition, comprising:

a continuous, biocompatible liquid phase comprising sterile thrombin having enzymatic activity; and

a solid phase comprising particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in said liquid phase,

said continuous liquid phase comprising said solid phase and said sterile thrombin substantially homogeneously dispersed there-through, wherein the ratio of said liquid phase and said solid phase is effective to provide said composition with hemostatic properties and wherein said sterile thrombin has lost not more than about 40 percent of the enzymatic activity possessed prior to sterilization.

2. The sterile hemostatic composition of claim 1 wherein said liquid phase comprises saline.

3. The sterile hemostatic composition of claim 2 wherein said biocompatible polymer is selected from the group consisting of proteins and polysaccharides.

4. The sterile hemostatic composition of claim 3 wherein said protein is selected from the group consisting of gelatin, collagen, fibrinogen and fibronectin.

5. The sterile hemostatic composition of claim 4 wherein said protein is gelatin.

6. The sterile hemostatic composition of claim 1 wherein said sterile thrombin has lost not more than about 20 percent of the enzymatic activity it possessed prior to sterilization.

Continuity (3)
Continuation 10567388
Provisional Application 60493116 · Aug 7, 2003
Related Publication 20100183582A1 · Jul 22, 2010